CA3096123A1 - Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses - Google Patents
Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses Download PDFInfo
- Publication number
- CA3096123A1 CA3096123A1 CA3096123A CA3096123A CA3096123A1 CA 3096123 A1 CA3096123 A1 CA 3096123A1 CA 3096123 A CA3096123 A CA 3096123A CA 3096123 A CA3096123 A CA 3096123A CA 3096123 A1 CA3096123 A1 CA 3096123A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- polypeptide
- multispecific
- polypeptide construct
- multispecific polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656331P | 2018-04-11 | 2018-04-11 | |
| US62/656,331 | 2018-04-11 | ||
| PCT/US2019/026860 WO2019200022A1 (en) | 2018-04-11 | 2019-04-10 | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3096123A1 true CA3096123A1 (en) | 2019-10-17 |
Family
ID=66248865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3096123A Pending CA3096123A1 (en) | 2018-04-11 | 2019-04-10 | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
Country Status (13)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| MY200973A (en) * | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| TW202010757A (zh) | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| US12590169B2 (en) | 2018-10-11 | 2026-03-31 | Inhibrx Biosciences, Inc. | 5T4 single domain antibodies and therapeutic compositions thereof |
| JP7611820B2 (ja) | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Dll3シングルドメイン抗体およびその治療用組成物 |
| CN113166261A (zh) * | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | B7h3单域抗体及其治疗性组合物 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| EP3930850A1 (en) | 2019-03-01 | 2022-01-05 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| JP7671275B2 (ja) | 2019-08-29 | 2025-05-01 | エランコ・ユーエス・インコーポレイテッド | 動物用の抗il31抗体 |
| CA3156761A1 (en) * | 2019-10-22 | 2021-04-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors |
| JP7738914B2 (ja) * | 2019-12-05 | 2025-09-16 | アーベル リミテッド | TriAx抗体の組成、その製造方法及び使用方法 |
| PH12022551470A1 (en) * | 2019-12-18 | 2023-05-03 | Janssen Biotech Inc | Materials and methods for in vivo biological targeting |
| EP4097129A1 (en) | 2020-01-29 | 2022-12-07 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| US12673992B2 (en) | 2020-02-13 | 2026-07-07 | UCB Biopharma SRL | Bispecific antibodies against CD9 and CD7 |
| EP4103611B1 (en) * | 2020-02-13 | 2024-03-27 | UCB Biopharma SRL | Bispecific antibodies binding hvem and cd9 |
| EP4103612A1 (en) * | 2020-02-13 | 2022-12-21 | UCB Biopharma SRL | Bispecific antibodies against cd9 |
| MX2022010176A (es) * | 2020-02-20 | 2023-01-16 | Win Therapeutics Inc | Moléculas de unión biespecíficas a gd2 y b7h2 y métodos de uso. |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| KR102846963B1 (ko) * | 2020-08-05 | 2025-08-18 | 신테카인, 인크. | IL27Rα 결합 분자 및 사용 방법 |
| MX2023001491A (es) | 2020-08-05 | 2023-03-08 | Synthekine Inc | Moleculas de union a gp130 y metodos de uso. |
| EP4192502A4 (en) | 2020-08-05 | 2024-10-09 | Synthekine, Inc. | Compositions and methods related to il27 receptor binding |
| WO2022042576A1 (zh) * | 2020-08-27 | 2022-03-03 | 盛禾(中国)生物制药有限公司 | 一种多功能融合蛋白及其用途 |
| KR20230086765A (ko) | 2020-10-13 | 2023-06-15 | 얀센 바이오테크 인코포레이티드 | 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법 |
| WO2022180271A1 (en) * | 2021-02-26 | 2022-09-01 | LAVA Therapeutics N.V. | Antibodies that bind CD123 and gamma-delta T cell receptors |
| WO2022190016A1 (en) * | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based multi-specific t-cell engagers |
| KR20230169182A (ko) * | 2021-04-09 | 2023-12-15 | 몰리큘라 파트너스 아게 | 신규한 DARPin 기반 CD70 인게이저 |
| CN113214402B (zh) * | 2021-06-03 | 2022-06-07 | 上海交通大学 | 分离的抗原结合蛋白及其应用 |
| CN118556083A (zh) * | 2021-10-12 | 2024-08-27 | 乐普创一生物科技(上海)有限公司 | 具有改善的治疗指数的靶向cd3的t细胞衔接器 |
| EP4416182A4 (en) * | 2021-10-12 | 2025-09-17 | Lepu Biopharma Co Ltd | ANTI-CD3 ANTIBODIES WITH CROSS-REACTIVITY TO HUMAN AND CYNOMOLGUS PROTEINS |
| CN119053342A (zh) * | 2022-01-21 | 2024-11-29 | 礼进生物医药控股有限公司 | 用于亲合力受体交联和免疫调节的多特异性抗体 |
| WO2023196957A2 (en) * | 2022-04-08 | 2023-10-12 | The Wistar Institute Of Anatomy And Biology | Bispecific t cell engagers targeting tumor antigens |
| GB202210969D0 (en) * | 2022-07-27 | 2022-09-07 | Univ Birmingham | Activation induced marker assay |
| EP4720125A1 (en) | 2023-05-30 | 2026-04-08 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| EP4762093A1 (en) | 2023-08-14 | 2026-06-24 | Paragon Therapeutics, Inc. | Alpha 4 beta 7 integrin binding proteins and methods of use |
Family Cites Families (160)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6291159B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US7063943B1 (en) | 1990-07-10 | 2006-06-20 | Cambridge Antibody Technology | Methods for producing members of specific binding pairs |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| AU736707B2 (en) | 1997-06-11 | 2001-08-02 | Anaphore, Inc. | Trimerising module |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9823071D0 (en) | 1998-10-21 | 1998-12-16 | Affibody Technology Ab | A method |
| EP1002861A1 (en) | 1998-10-26 | 2000-05-24 | Unilever Plc | Antigen-binding proteins comprising a linker which confers restricted conformational flexibility |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| GB9917027D0 (en) | 1999-07-20 | 1999-09-22 | Affibody Technology Sweeden Ab | In vitro selection and optional identification of polypeptides using solid support carriers |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| CA2477192A1 (en) | 2000-05-18 | 2001-11-18 | Japan Tobacco, Inc. | Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof |
| AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| EP1353937A4 (en) | 2000-12-29 | 2005-04-13 | Savient Pharmaceuticals Inc | SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2441653A1 (en) | 2003-09-19 | 2005-03-19 | William Herman | Targeted ligands |
| HUE038955T2 (hu) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| PT1718677E (pt) | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
| BRPI0507169A (pt) | 2004-02-02 | 2007-06-26 | Ambrx Inc | polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos |
| CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| JP2008507280A (ja) | 2004-07-21 | 2008-03-13 | アンブレツクス・インコーポレイテツド | 非天然コードアミノ酸を用いた生合成ポリペプチド |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| WO2006053568A1 (en) | 2004-11-22 | 2006-05-26 | Borean Pharma Aps | Tnf antagonists |
| NZ555308A (en) | 2004-12-22 | 2010-10-29 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| AU2006232310B9 (en) | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
| JP5838021B2 (ja) | 2005-04-15 | 2015-12-24 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディとその使用 |
| HRP20110404T1 (hr) | 2005-11-08 | 2011-08-31 | Ambrx | Ubrzivači za modifikaciju ne-prirodnih aminokiselina i polipeptida ne-prirodnih aminokiselina |
| SG170091A1 (en) | 2006-03-10 | 2011-04-29 | Wyeth Corp | Anti-5t4 antibodies and uses thereof |
| KR20090060294A (ko) | 2006-09-08 | 2009-06-11 | 암브룩스, 인코포레이티드 | 변형된 인간 혈장 폴리펩티드 또는 Fc 스캐폴드 및 그의 용도 |
| CN101675071B (zh) | 2007-05-02 | 2014-06-18 | Ambrx公司 | 经修饰干扰素β多肽和其用途 |
| BRPI0811466A2 (pt) | 2007-05-07 | 2014-10-14 | Medimmune Llc | Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica. |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| AU2016213702C1 (en) | 2007-08-22 | 2018-11-29 | Cytomx Therapeutics, Inc. | Activatable binding polypeptides and methods of identification and use thereof |
| AU2013202755B2 (en) | 2007-08-22 | 2016-05-12 | Cytomx Therapeutics, Inc. | Activatable binding polypeptides and methods of identification and use thereof |
| EP2190861A4 (en) | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| US20100254998A1 (en) | 2007-09-03 | 2010-10-07 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | Method for prolonging longevity |
| CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| TW200944231A (en) | 2007-11-30 | 2009-11-01 | Glaxo Group Ltd | Antigen-binding constructs |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| AU2015202560B2 (en) | 2008-01-07 | 2017-06-15 | Amgen Inc. | Method for Making Antibody Fc-Heterodimeric Molecules Using Electrostatic Steering Effects |
| WO2009117622A2 (en) | 2008-03-19 | 2009-09-24 | Ambrx, Inc. | Modified fgf-23 polypeptides and their uses |
| US8557965B2 (en) | 2008-04-07 | 2013-10-15 | Ablynx N.V. | Single variable domains against notch pathway members |
| US20110097339A1 (en) | 2008-07-18 | 2011-04-28 | Domantis Limited | Compositions monovalent for CD28 binding and methods of use |
| MX2011000501A (es) | 2008-07-18 | 2011-05-23 | Squibb Bristol Myers Co | Composiciones monovalentes para union a cd28 y metodos de uso. |
| EP2318029B1 (en) | 2008-07-23 | 2017-11-01 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
| US8278418B2 (en) | 2008-09-26 | 2012-10-02 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
| MX2011003502A (es) | 2008-10-01 | 2011-09-01 | Micromet Ag | Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies. |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| CN102361884A (zh) * | 2009-04-07 | 2012-02-22 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-2/抗-c-Met抗体 |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| BR112013002167A2 (pt) | 2010-08-24 | 2016-05-31 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| WO2012162067A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| WO2012162583A1 (en) | 2011-05-26 | 2012-11-29 | Ibc Pharmaceuticals, Inc. | Design and construction of novel multivalent antibodies |
| MX2014003313A (es) | 2011-09-23 | 2014-07-09 | Amgen Res Munich Gmbh | Moleculas de union biespecificas para 5t4 y cd3. |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
| TWI476001B (zh) | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Fc融合蛋白及其用途 |
| KR101814370B1 (ko) | 2011-12-27 | 2018-01-12 | 재단법인 생물기술개발중심 | 경쇄-가교된 이중특이성 항체 |
| ME03512B (me) | 2012-02-06 | 2020-04-20 | Inhibrx Inc | Cd47 antitijela i postupci za njihovu upotrebu |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| BR112015000798A2 (pt) | 2012-07-13 | 2017-06-27 | Zymeworks Inc | heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 |
| CN104640561A (zh) | 2012-07-23 | 2015-05-20 | 酵活有限公司 | 包含轻链和重链的选择性配对的免疫球蛋白构建体 |
| US20150239991A1 (en) | 2012-09-25 | 2015-08-27 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| MX2015003616A (es) | 2012-10-08 | 2015-06-05 | Roche Glycart Ag | Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso. |
| CA2889951C (en) | 2012-11-02 | 2023-04-18 | Zymeworks Inc. | Crystal structures of heterodimeric fc domains |
| EP2920209B1 (en) | 2012-11-13 | 2020-08-05 | BioNTech SE | Agents for treatment of claudin expressing cancer diseases |
| EA032681B1 (ru) | 2012-11-27 | 2019-07-31 | Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн | ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ |
| SMT201900242T1 (it) | 2012-12-03 | 2019-05-10 | Bristol Myers Squibb Co | Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici |
| US9703815B2 (en) | 2012-12-17 | 2017-07-11 | Salesforce.Com, Inc. | Third party files in an on-demand database service |
| KR20150095684A (ko) | 2012-12-18 | 2015-08-21 | 노파르티스 아게 | 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법 |
| KR102391731B1 (ko) | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) * | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| ES2699599T3 (es) | 2013-03-15 | 2019-02-11 | Abbvie Biotherapeutics Inc | Variantes de Fc |
| EP3587448B1 (en) * | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Heterodimeric proteins |
| JP6693872B2 (ja) | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス,インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
| KR20250051130A (ko) | 2013-09-25 | 2025-04-16 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| EP3628328B1 (en) | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| JP2017514522A (ja) | 2014-05-02 | 2017-06-08 | エモリー ユニバーシティー | ヒト化可変性リンパ球受容体(vlr)および組成物ならびにそれに関連する使用 |
| US20170103186A1 (en) | 2014-06-03 | 2017-04-13 | Amgen Inc. | Systems and methods for supporting patient use of a drug delivery device |
| GB201411420D0 (en) * | 2014-06-26 | 2014-08-13 | Ucb Biopharma Sprl | Antibody constructs |
| AU2015279321B2 (en) | 2014-06-27 | 2021-03-04 | Innate Pharma, S.A. | Multispecific antigen binding proteins |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| WO2016019300A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| PL3177643T3 (pl) | 2014-08-04 | 2019-09-30 | F.Hoffmann-La Roche Ag | Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T |
| EP2982693A1 (en) | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| KR102485788B1 (ko) | 2014-08-27 | 2023-01-09 | 메모리얼 슬로안 케터링 캔서 센터 | 항체, 조성물 및 용도 |
| WO2016034666A1 (en) | 2014-09-04 | 2016-03-10 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| EP3197916A2 (en) | 2014-09-25 | 2017-08-02 | Amgen Inc. | Protease-activatable bispecific proteins |
| JP2017536341A (ja) | 2014-10-09 | 2017-12-07 | エンクマフ アーゲー | 卵巣がんの処置における使用のためのCD3εおよびROR1に対する二特異性抗体 |
| JP6696982B2 (ja) | 2014-11-26 | 2020-05-20 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd3および腫瘍抗原に結合するヘテロ二量体抗体 |
| WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| ES2935274T3 (es) | 2014-12-05 | 2023-03-03 | Merck Patent Gmbh | Anticuerpo con intercambio de dominios |
| MX384198B (es) | 2014-12-19 | 2025-03-14 | Chiome Bioscience Inc | Proteina de fusion que comprende tres dominios de union a 5t4 y cd3. |
| US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| CA3081058C (en) | 2015-01-16 | 2024-02-20 | Academia Sinica | Linker units and their uses in configuring pharmaceutical molecules |
| IL300408B2 (en) | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| EP3247407A4 (en) | 2015-01-21 | 2018-08-22 | Inhibrx LP | Non-immunogenic single domain antibodies |
| MA41613A (fr) | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| ES2984656T3 (es) | 2015-05-13 | 2024-10-30 | Ablynx Nv | Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3 |
| WO2016192613A1 (zh) | 2015-06-01 | 2016-12-08 | 中山大学 | 具有融合至常规Fab片段的单域抗原结合片段的二价抗体 |
| JP6807606B2 (ja) | 2015-07-16 | 2021-01-06 | インヒブルクス インコーポレイテッド | 多価及び多重特異性dr5結合融合タンパク質 |
| EP3325512B1 (en) | 2015-07-23 | 2023-09-06 | Inhibrx, Inc. | Multivalent and multispecific gitr-binding fusion proteins |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| JP2018523686A (ja) | 2015-08-17 | 2018-08-23 | マクロジェニクス,インコーポレーテッド | B7‐h3及びcd3に結合できる二重特異性1価ダイアボディ並びにその使用 |
| MY206406A (en) | 2015-10-02 | 2024-12-16 | Hoffmann La Roche | Bispecific antibodies specific for a costimulatory tnf receptor |
| PE20181349A1 (es) | 2015-10-07 | 2018-08-22 | Hoffmann La Roche | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador |
| IL300122A (en) | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| JP7328761B2 (ja) | 2016-01-11 | 2023-08-17 | インヒブルクス インコーポレイテッド | 多価多重特異性ox40結合融合タンパク質 |
| IL304871A (en) | 2016-01-11 | 2023-10-01 | Inhibrx Inc | Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses |
| GB201602156D0 (en) | 2016-02-05 | 2016-03-23 | Jones Philip C And Boku University Of Natural Resources And Life Sciences | Heterodimers and purification thereof |
| US20190112380A1 (en) | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| ES3056995T3 (en) | 2016-04-13 | 2026-02-25 | Vivia Biotech Sl | Ex vivo bite-activated t cells |
| BR112018071612A2 (pt) | 2016-04-22 | 2019-02-19 | Alligator Bioscience Ab | polipeptídeos biespecíficos inovadores contra cd137 |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| WO2018027025A1 (en) | 2016-08-03 | 2018-02-08 | Oncomed Pharmaceuticals, Inc. | Cd40-binding agents and uses thereof |
| CN108084265B (zh) | 2016-11-23 | 2021-07-02 | 复旦大学 | 特异性结合人的5t4抗原的全人源单域抗体及其应用 |
| CA3047070A1 (en) | 2017-01-03 | 2018-07-12 | F.Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
| EP3595705A1 (en) | 2017-03-15 | 2020-01-22 | Oxford BioMedica (UK) Limited | Method |
| CN110402255B (zh) | 2017-04-04 | 2022-12-02 | 豪夫迈·罗氏有限公司 | 新颖的能够特异性结合cd40和fap的双特异性抗原结合分子 |
| MY200973A (en) * | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| EP3502140A1 (en) | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
| TW202010757A (zh) | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
| WO2019201866A1 (en) | 2018-04-16 | 2019-10-24 | Swedish Orphan Biovitrum Ab (Publ) | Fusion protein |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| CN113166261A (zh) | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | B7h3单域抗体及其治疗性组合物 |
| JP7611820B2 (ja) | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Dll3シングルドメイン抗体およびその治療用組成物 |
| AU2019356573B2 (en) | 2018-10-11 | 2025-12-18 | Inhibrx Biosciences, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
| US12590169B2 (en) | 2018-10-11 | 2026-03-31 | Inhibrx Biosciences, Inc. | 5T4 single domain antibodies and therapeutic compositions thereof |
| EP4097129A1 (en) | 2020-01-29 | 2022-12-07 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
-
2019
- 2019-04-10 TW TW108112538A patent/TW202010757A/zh unknown
- 2019-04-10 AU AU2019251488A patent/AU2019251488B2/en active Active
- 2019-04-10 BR BR112020020604-0A patent/BR112020020604A2/pt unknown
- 2019-04-10 SG SG11202009804RA patent/SG11202009804RA/en unknown
- 2019-04-10 CA CA3096123A patent/CA3096123A1/en active Pending
- 2019-04-10 WO PCT/US2019/026860 patent/WO2019200022A1/en not_active Ceased
- 2019-04-10 CN CN201980037529.1A patent/CN112218686A/zh active Pending
- 2019-04-10 IL IL323061A patent/IL323061A/en unknown
- 2019-04-10 US US16/380,963 patent/US20190330366A1/en not_active Abandoned
- 2019-04-10 KR KR1020267008973A patent/KR20260046525A/ko active Pending
- 2019-04-10 JP JP2020555516A patent/JP7724061B2/ja active Active
- 2019-04-10 MX MX2020010638A patent/MX2020010638A/es unknown
- 2019-04-10 IL IL277863A patent/IL277863B2/en unknown
- 2019-04-10 EP EP19719134.9A patent/EP3773913A1/en active Pending
- 2019-04-10 KR KR1020207032497A patent/KR102944523B1/ko active Active
-
2020
- 2020-10-08 MX MX2025010712A patent/MX2025010712A/es unknown
-
2023
- 2023-06-06 US US18/206,354 patent/US12331132B2/en active Active
-
2025
- 2025-03-19 JP JP2025044245A patent/JP7824455B2/ja active Active
- 2025-05-12 US US19/205,916 patent/US20250361319A1/en active Pending
-
2026
- 2026-02-19 JP JP2026025011A patent/JP2026077839A/ja active Pending
- 2026-05-11 AU AU2026203604A patent/AU2026203604A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019200022A1 (en) | 2019-10-17 |
| MX2025010712A (es) | 2025-10-01 |
| KR20260046525A (ko) | 2026-04-07 |
| BR112020020604A2 (pt) | 2021-01-12 |
| JP2025102819A (ja) | 2025-07-08 |
| JP2021520812A (ja) | 2021-08-26 |
| IL323061A (en) | 2025-10-01 |
| MX2020010638A (es) | 2021-01-08 |
| JP2026077839A (ja) | 2026-05-13 |
| AU2019251488A1 (en) | 2020-10-22 |
| IL277863A (en) | 2020-11-30 |
| AU2026203604A1 (en) | 2026-05-28 |
| US12331132B2 (en) | 2025-06-17 |
| JP7724061B2 (ja) | 2025-08-15 |
| KR102944523B1 (ko) | 2026-03-25 |
| SG11202009804RA (en) | 2020-11-27 |
| CN112218686A (zh) | 2021-01-12 |
| JP7824455B2 (ja) | 2026-03-04 |
| KR20210006913A (ko) | 2021-01-19 |
| IL277863B1 (en) | 2025-10-01 |
| IL277863B2 (en) | 2026-02-01 |
| TW202010757A (zh) | 2020-03-16 |
| US20230295336A1 (en) | 2023-09-21 |
| US20190330366A1 (en) | 2019-10-31 |
| EP3773913A1 (en) | 2021-02-17 |
| AU2019251488B2 (en) | 2026-02-12 |
| US20250361319A1 (en) | 2025-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12331132B2 (en) | Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses | |
| US20240101704A1 (en) | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same | |
| US20250092137A1 (en) | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same | |
| RU2813816C2 (ru) | Полиспецифические полипептидные конструкции, обладающие ограниченным связыванием с сd3, и способы их применения | |
| BR122024001310A2 (pt) | Construções de polipeptídeo multiespecífico, métodos de produção e usos dos mesmos, polinucleotídeo(s), vetor, célula, e composição farmacêutica e seus usos | |
| NZ758264B2 (en) | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220928 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: N-6-6-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20240704 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240704 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: N-6-6-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20240823 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240829 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20240906 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241028 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: N-6-6-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250114 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250114 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250114 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250114 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250205 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: N-6-6-R10-R00-R125 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMMON REPRESENTATIVE APPOINTED Effective date: 20250313 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: N-6-6-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250313 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250322 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250404 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250404 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250505 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250905 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250913 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251107 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251107 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260403 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260403 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260728 |